Table 1.
Clinical data of 25 enrolled subjects with CAE.
| Subject |
Sex/age (F or M/years) |
Duration of epilepsy (months) | Seizure frequency (times/day) | AED at the time of recording |
|---|---|---|---|---|
| 1 | F/7 | 1 | 20 | None |
| 2 | F/6 | 12 | 10 | None |
| 3 | M/7 | 25 | 10 | VPA and LTG |
| 4 | F/10 | 24 | 5–7 | LTG |
| 5 | F/8 | 3 | 20 | None |
| 6 | F/9 | 60 | 2–5 | None |
| 7 | M/8 | 2 | 5–8 | VPA |
| 8 | F/7 | 4 | 10 | VPA |
| 9 | F/5 | 2 | 7–8 | None |
| 10 | F/10 | 10 | 4–5 | None |
| 11 | F/9 | 3 | 15–20 | None |
| 12 | M/14 | 6 | 2–3 | OXC |
| 13 | F/10 | 11 | 4–5 | None |
| 14 | F/5 | 5 | 1–2 | None |
| 15 | F/6.5 | 4 | 5–6 | None |
| 16 | F/5.5 | 24 | 6–8 | OXC and LTG |
| 17 | F/5 | 2 | 10 | None |
| 18 | F/6 | 12 | 8–10 | VPA |
| 19 | F/8 | 1 | 4–5 | VPA |
| 20 | M/7 | 1 | 0–1 | VPA |
| 21 | M/10 | 72 | 4–5 | VPA |
| 22 | F/8 | 24 | 0–1 | VPA |
| 23 | F/6 | 2 | 5–10 | None |
| 24 | M/7.5 | 5 | 2–3 | VPA |
| 25 | M/8 | 4 | 10 | None |
F, female; M, male; VPA, valproate; OXG, oxcarbazepine; LTG, lamotrigine; CAE, childhood absence epilepsy; AED, antiepileptic drug.